Faron Pharmaceuticals Oy Stock Working Capital
| FARN Stock | 165.00 10.00 5.71% |
Faron Pharmaceuticals Oy fundamentals help investors to digest information that contributes to Faron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Faron Stock. The fundamental analysis module provides a way to measure Faron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Faron Pharmaceuticals stock.
Change In Working Capital is likely to gain to about 3.4 M in 2024, despite the fact that Net Working Capital is likely to grow to (5.8 M). Faron | Working Capital |
Faron Pharmaceuticals Oy Company Working Capital Analysis
Faron Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Faron Pharmaceuticals Working Capital | (6.14 M) |
Most of Faron Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Faron Pharmaceuticals Oy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Faron Net Invested Capital
Net Invested Capital |
|
According to the company's disclosures, Faron Pharmaceuticals Oy has a Working Capital of (6.14 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The working capital for all United Kingdom stocks is notably higher than that of the company.
Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Faron Fundamentals
| Return On Equity | -39.61 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 158.38 M | ||||
| Shares Outstanding | 104.62 M | ||||
| Shares Owned By Insiders | 31.81 % | ||||
| Shares Owned By Institutions | 10.35 % | ||||
| Price To Book | 151.61 X | ||||
| Price To Sales | 16.21 X | ||||
| Gross Profit | 803 K | ||||
| EBITDA | (28.37 M) | ||||
| Net Income | (30.94 M) | ||||
| Total Debt | 13.11 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (23.81 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Target Price | 1006.71 | ||||
| Number Of Employees | 34 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 172.63 M | ||||
| Total Asset | 10.22 M | ||||
| Retained Earnings | (172.21 M) | ||||
| Working Capital | (6.14 M) | ||||
| Net Asset | 10.22 M |
About Faron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Faron Pharmaceuticals Oy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Faron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Faron Pharmaceuticals Oy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.